Rajendran Alappan, MD
Nephrology · Columbus, GANPI 1225024557
Payments from drug & device makers
Across 445 payments — averaging $777.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$227K
- AstraZeneca$61K
- GSK$48K
- Fresenius USA Marketing, Inc.$4K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Bayer$334
- plus $2K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 173 | $227,015 |
| AstraZeneca(2 entities) | 100 | $60,749 |
| GSK | 41 | $47,828 |
| Fresenius USA Marketing, Inc. | 11 | $4,165 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $3,430 |
| Bayer | 12 | $334 |
| Travere Therapeutics, Inc. | 23 | $311 |
| Amgen(2 entities) | 11 | $290 |
| OPKO Pharmaceuticals, LLC | 20 | $285 |
| Mallinckrodt Hospital Products Inc. | 8 | $236 |
| Baxter Healthcare | 5 | $206 |
| Novo Nordisk | 11 | $171 |
| Novartis | 7 | $141 |
| Otsuka America Pharmaceutical, Inc. | 4 | $135 |
| Mallinckrodt Enterprises LLC | 3 | $120 |
| Valeritas, Inc. | 1 | $90 |
| Calliditas Therapeutics US Inc. | 3 | $58 |
| Amarin Pharma, Inc. | 1 | $57 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| Boehringer Ingelheim | 1 | $25 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Ardelyx, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| Fresenius USA Manufacturing, Inc. | 1 | $16 |
How this compares
$345,799 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Columbus
- Tamorie SmithColumbus$1.9M
- Rajeev ChauhanColumbus$1.1M
- Arachelvi DhandayuthapaniColumbus$110K
- Fahd SyedColumbus$48K
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
- Barton BrezinaAugusta$1.5M
- Frederic Rahbari OskouiAtlanta$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.